← Back to patent-cliff list
H3B-6545
Tier C — Watch / tradeH3B-6545
H3 Biomedicine Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERα
Indications (approved)：Breast cancer
Regional status
US
Phase II
2017-08-23
EU
Phase II
2017-08-23
China
-
Japan
Phase I
2020-09-30
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of H3B-6545?
Approved indications include: Breast cancer.
When does the H3B-6545 patent expire?
No public expiry year is available for H3B-6545 yet; this page updates once verified.
How do I get a quote for H3B-6545 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09